



## Clinical trial results:

**A phase IIIb, open-label, non-randomised, multicentre study to assess the immunogenicity and safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine when administered intramuscularly according to a 2-dose schedule in healthy female adolescents or intramuscularly according to a 3-dose schedule in healthy female adults, 6.5 years after first vaccine dose in study HPV-048 PRI (110659).**

### Summary

EudraCT number	2014-000060-17
Trial protocol	DE
Global end of trial date	29 July 2014

### Results information

Result version number	v1 (current)
This version publication date	22 December 2018
First version publication date	22 December 2018
Summary attachment (see zip file)	Cancelled before Active Statement (2014-000060-17) (Cancelled before Active Statement (2014-000060-17).pdf)

### Trial information

#### Trial identification

Sponsor protocol code	200255
-----------------------	--------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, +44 2089904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, +44 2089904466, GSKClinicalSupportHD@gsk.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 July 2014
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	29 July 2014
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

To assess the persistence of anti-HPV-16 and anti-HPV-18 antibodies [by Enzyme Linked Immunosorbent assay (ELISA)] in subjects, previously vaccinated with either two or three doses of GSK Biologicals' HPV-16/18 vaccine according to a 0, 6-months schedule or a 0, 1, 6-months schedule in the study HPV-048 PRI (110659).

Protection of trial subjects:

The study was cancelled before active (see attached statement). No patient entered the study, therefore no results / data are available.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	29 July 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 99999
Worldwide total number of subjects	99999
EEA total number of subjects	99999

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	99999
Adults (18-64 years)	0

From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

99999 is "Not applicable" value or 0 participants, the study was cancelled before active. No patient entered the study, therefore no results / data are available.

### Pre-assignment

Screening details:

Study cancelled before active (see attached statement)

### Period 1

Period 1 title	Cancelled before active period (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

<b>Arm title</b>	No-Arm
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Cervarix
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

The product was not administered as the study was cancelled before active.

<b>Number of subjects in period 1</b>	No-Arm
Started	99999
Completed	99999

## Baseline characteristics

### Reporting groups

Reporting group title	Cancelled before active period
-----------------------	--------------------------------

Reporting group description: -

Reporting group values	Cancelled before active period	Total	
Number of subjects	99999	99999	
Age categorical Units: Subjects			
Age continuous Units: years arithmetic mean standard deviation	0 ± 0	-	
Gender categorical Units: Subjects			
Female	99999	99999	
Male	0	0	

## End points

### End points reporting groups

Reporting group title	No-Arm
Reporting group description: -	

### Primary: No endpoint results

End point title	No endpoint results <sup>[1]</sup>
End point description:	

End point type	Primary
----------------	---------

End point timeframe:

The study was cancelled before active (see attached statement)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The study was cancelled before active (see attached statement).

<b>End point values</b>	No-Arm			
Subject group type	Reporting group			
Number of subjects analysed	99999			
Units: Subjects	99999			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

---

### Adverse events information<sup>[1]</sup>

---

Timeframe for reporting adverse events:

The study was cancelled before active (see attached statement)

Assessment type	Systematic
-----------------	------------

---

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

---

Dictionary version	0
--------------------	---

---

Frequency threshold for reporting non-serious adverse events: 0 %

---

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: The study was cancelled before active (see attached statement).

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
29 July 2014	The study was cancelled before active (see attached statement).	-

Notes:

### Limitations and caveats

None reported